Funder: National Institutes of Health
Due Dates: November 5, 2026 (Renewal/resubmission/revision) | February 5, 2027 (New) | March 5, 2027 (Renewal/resubmission/revision) | June 5, 2027 (New) | July 5, 2027 (Renewal/resubmission/revision) | October 5, 2027 (New) | November 5, 2027 (Renewal/resubmission/revision) | February 5, 2028 (New) | March 5, 2028 (Renewal/resubmission/revision) | June 5, 2028 (New) | July 5, 2028 (Renewal/resubmission/revision) | October 5, 2028 (New) | November 5, 2028 (Renewal/resubmission/revision) | February 5, 2029 (New) | March 5, 2029 (Renewal/resubmission/revision) | June 5, 2029 (New) | July 5, 2029 (Renewal/resubmission/revision; final closing)
Funding Amounts: $500,000 award ceiling; application budgets below $500,000 in annual direct costs; up to 5 years
Summary: Supports multidisciplinary bioengineering teams developing, optimizing, validating, or translating technologies to solve biomedical problems.
Key Information: Technology development or adaptation is required; unmodified existing technologies and phase III clinical trials are not supported.
Description
NIH’s Bioengineering Research Grants program supports small teams bridging the life and physical sciences to develop innovative technologies, models, techniques, designs, and methods. Through the R01 mechanism, it funds design-directed, developmental, discovery-driven, or hypothesis-driven research that integrates quantitative sciences with biomedical research. Participating institutes are NCI, NEI, NICHD, and NINDS.
Projects should accelerate the adoption of promising tools for specific basic, translational, or clinical problems. Examples include predictive biological models, improved measurement technologies, delivery systems, tissues, therapeutics, implants, and prosthetics. Innovation can include combining existing components to create new capabilities or efficiencies. Clinical trials are optional, but supported trials must test functionality or validate performance with translation as the primary motivation.
